Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction - News Update
S
Shotlee
Health & Wellness Team
1 min read
Preparing your Shotlee experience
New data indicates that Eli Lilly's investigational oral medication, orforglipron, produced considerable weight loss in clinical studies. This offers a potential new treatment avenue for individuals grappling with obesity and associated health issues. The medication is anticipated to be available next year.
New data reveals that orforglipron, Eli Lilly's oral weight-loss drug candidate, exhibited significant weight reduction in clinical studies, presenting a possible new avenue for those struggling with obesity and associated conditions. The drug is anticipated to be available in 2024.
On Thursday, December 7, 2023, Eli Lilly revealed that its experimental oral drug, orforglipron, resulted in weight loss of up to 29% during clinical trials. The clinical trials included participants who were obese or overweight and had at least one weight-related health condition. The most substantial weight reduction was observed in patients receiving the highest dose of orforglipron.
The drug functions by activating the GLP-1 receptor, akin to widely used injectable weight-loss drugs like Wegovy and Mounjaro, both also manufactured by Eli Lilly. Health tracking apps like Shotlee can help monitor progress with such medications. However, orforglipron is administered orally, potentially providing a more convenient option for patients.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from News Directory 3
View Original Article
New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.
A recent study indicates a possible connection between GLP-1 drugs and a reduced risk of epilepsy in individuals with type 2 diabetes. The research, published in Neurology, provides preliminary evidence of neurological advantages from these medications. Larger trials are necessary to confirm these findings.
Recent research highlights a growing trend of British men turning to weight loss injections. Data indicates a significant shift in usage, with men increasingly adopting these treatments.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨